CDMO News

Johnson & Johnson and Legend Biotech Expand Manufacturing Deal with Novartis

  • Johnson & Johnson and Legend Biotech have expanded their manufacturing deal with Novartis to increase the production of Carvykti.
  • The agreement covers Carvykti supply for clinical trials outside of China.

Johnson & Johnson and Legend Biotech have announced the expansion of their partnership with Novartis to manufacture their multiple myeloma treatment, CAR-T Caryvkti until the end of 2029.

The deal will see Novartis supply Carvykti from its cell therapy site in Morris Plains, New Jersey. This site is located just 20 miles from Johnson & Johnson and Legend’s CAR-T facility in Raritan, New Jersey.

Sign up to the free weekly newsletter for all the latest news, resources and podcasts in contract manufacturing.  Register here

The Science of Partnering

LIVE on June 13 2024    

CDMO Live is the ultimate online event for bio/pharma outsourcing

Discover the latest trends and best practices in contract manufacturing, and connect with leading partners. 

The Science of Partnering

CDMO Live is the ultimate online event for bio/pharma outsourcing

Discover the latest trends and best practices in contract manufacturing, and connect with leading partners. 

LIVE on June 13 2024    Register today

Who do you rate?
Recommend a Supplier

Help us find the most innovative and trusted suppliers in Pharma and Biotech.